Alvogen is one of the fastest growing pharmaceutical companies in the world with commercial presence in over 35 countries. We improve people’s lives by making high-quality medicines more ...

“This is an industry which requires a high level of investment, has relatively high barriers to entry and superior quality requirements compared to other industries,” said Robert Wessman, CEO and ...

NRx Pharmaceuticals (Nasdaq: NRXP) recently shared its financials and offered updates on its business operations from the ...

Wessman also founded Alvogen, a contract manufacturing organization ("CMO") based in the US which went to become another generics drug company of renown. A biosimilar is a biological medicine that ...

Collegium's move also follows victory for BDSI in a patent infringement lawsuit with Alvogen which if unchallenged will prevent the latter from launching a generic version of Belbuca until 2032.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, a U.S. law firm, announced on Monday its acquisition of a life sciences patent ...

Q1 2024 Earnings Call Transcript May 14, 2024 Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals, Inc. First Quarter of 2024 Results Conference Call [Operator Instructions]. As ...

Gutman has represented Alvogen Pine Brook, Amgen, Natco Pharma and Oxford Immunotec Global in prior patent fights. "Sige is regarded as one of the top life sciences patent litigators in the country," ...

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has the potential to act as a ...

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) Q1 2024 Earnings Call Transcript May 9, 2024 Collegium Pharmaceutical, Inc.